WESTBURY, N.Y., April 19 / PRNewswire / — Tishcon Corp. announced that the U.S. FDA has granted the firm Orphan Drug Designations for UBIQUINOL (Coenzyme Q10) in the treatment of Pediatric Congestive Heart Failure and Huntington’s Disease.
![](https://www.tishcon.com/wp-content/uploads/2022/04/qgel-q10.png)
WESTBURY, N.Y., April 19 / PRNewswire / — Tishcon Corp. announced that the U.S. FDA has granted the firm Orphan Drug Designations for UBIQUINOL (Coenzyme Q10) in the treatment of Pediatric Congestive Heart Failure and Huntington’s Disease.